ADx System
Description:The
ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
Company:Abbott Diagnostics
Identity® Adx Pacemaker
Description:The Identity
ADx pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with the most advanced pacemaker technology available, including the revolutionary AF Suppression™ algorithm, the first and only U.S. commercially approved algorithm designed to suppress atrial fibrillation (AF)....
Company:St. Jude Medical, Inc.
Integrity® Adx Pacemaker
Description:The Integrity
ADx pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with advanced pacemaker technology, including the revolutionary AF Suppression™ algorithm, the first U.S. commercially approved algorithm designed to suppress atrial fibrillation (AF)....
Company:St. Jude Medical, Inc.
Verity Adx Pacemaker
Description:The Verity
ADx pacemaker family, which includes the world's longest lasting single- and dual-chamber pacemakers, provides clinicians with a variety of feature options and header configurations to meet various clinical needs....
Company:St. Jude Medical, Inc.
TVL™ ADX Leads
Description:The TVL-
ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margins....
Company:St. Jude Medical, Inc.
Addex Reports Positive Results in Phase IIa Clinical Trial With
ADX10059 in Migraine
GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticalsannounced today the successful completion of a Phase IIa proof ofconcept trial with its lead compound
ADX10059 in patients withmigraine. The study achieved its primary objective, the absence ofpain at 2 hours after dosing, with statistical significance, andalso showed trends towards improvement in pain-free status andimprovement...
Addex Achieves Statistically Significant Outcome in Phase IIa
Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
GENEVA, April 17, 2007 /PRNewswire/ -- Addex Pharmaceuticalsannounced today the successful completion of a Phase IIa proof ofconcept trial with its lead compound
ADX10059 in patients withgastro-esophageal reflux disease (GERD), a highly prevalentcondition with a significant unmet medical need. The study achievedits primary objective, the control of 24-hour esophageal pH, withstatistical...